Factor V Leiden: should we screen oral contraceptive users and pregnant women?
Key result
Universal screening for Factor V Leiden, present in about 5% of the white population, is not recommended before oral contraceptive use or pregnancy due to the low number of prevented deaths.
Why the study?
Should oral contraceptive users and pregnant women be universally screened for the factor V Leiden mutation?
Population
Women who use oral contraceptives and pregnant women
Comparison
Universal screening for the factor V Leiden… vs Taking a personal and family history of deep…
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Universal screening for factor V Leiden in women seeking oral contraceptives or during pregnancy is not recommended due to the unfavorable balance of preventing rare pulmonary emboli versus the risks of fatal bleeding from subsequent anticoagulation.
Structured PICO
Should oral contraceptive users and pregnant women be universally screened for the factor V Leiden mutation?
P
Population
Women who use oral contraceptives and pregnant women
I
Intervention
Universal screening for the factor V Leiden mutation before prescription of oral contraceptives and during pregnancy
C
Comparator
Taking a personal and family history of deep vein thrombosis
O
Outcome
Deaths due to pulmonary emboli and fatal bleedinghard clinical
Universal screening for factor V Leiden in women seeking oral contraceptives or during pregnancy is not recommended due to the unfavorable balance of preventing rare pulmonary emboli versus the risks of fatal bleeding from subsequent anticoagulation.
Cite This Study
Vandenbroucke et al. (1996) conducted an editorial in Deep vein thrombosis. Universal screening for Factor V Leiden was evaluated. Universal screening for Factor V Leiden, present in about 5% of the white population, is not recommended before oral contraceptive use or pregnancy due to the low number of prevented deaths.